Results 11 to 20 of about 40,708 (270)

Efficacy of naltrexone and bupropion combination in patients with binge eating disorder: a systematic review and meta-analysis. [PDF]

Eat Weight Disord
Roudbaraki SN, Salimi M, Esmailpour S, Mohammadi F.   +3 more
europepmc   +3 more sources

Visual hallucinations associated with bupropion use: a case report

Psychiatry and Clinical Psychopharmacology, 2021
Bupropion is an antidepresant that acts as a norepinephrine and dopamine reuptake inhibitor and has a favorable side-effect profile. The most common side-effects of this drug include insomnia, constipation, headache and dry mouth.
Sevda Korkmaz, Murat Kuloğlu, Sadullah Sağlam, Murad Atmaca   +3 more
doaj   +1 more source

GP prescribing of nicotine replacement and bupropion to aid smoking cessation in England and Wales [PDF]

, 2004
Aims Prescribing nicotine replacement therapy (NRT) or bupropion for smoking cessation is of considerable importance to public health but little is known about prescribing practices.
McEwen, A, Owen, L, West, R
core   +1 more source

Part Two: Evaluation of N-methylbupropion as a Potential Bupropion Prodrug

Pharmaceuticals, 2014
N-methylbupropion was selected as a potential prodrug from our in vitro screening of analogues of bupropion described in the preceding paper. This study describes in vivo pharmacokinetics of N-methylbupropion in the guinea-pig animal model, which is ...
Paul Matthew O'Byrne, Robert williams, John J. walsh, John F. Gilmer   +3 more
doaj   +1 more source

Efficacy of varenicline versus bupropion for smoking cessation: A systematic review and meta-analysis of randomized controlled trials

Indian Journal of Psychiatry, 2023
According to the Global Burden of Disease (GBD) Study conducted in 2019, smoking tobacco leads to over 8 million deaths each year. Hence, it is crucial to identify optimal smoking cessation therapy. To compare the efficacy of varenicline versus bupropion
Ashish R. Patel, Jigar R. Panchal, Chetna K. Desai   +2 more
doaj   +1 more source

“Ghost tablet” husks excreted in feces in large bupropion XL overdose [PDF]

, 2018
Background: Extended-release medications are widely prescribed across the spectrum of medical specialties; however, there is heterogeneity in how they are formulated.
Nanagas, Kristine, Overberg, Adam, Purpura, Andrea   +2 more
core   +1 more source

A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response [PDF]

, 2008
The pregnane X receptor (PXR) and the constitutive androstane receptor (CAR) are closely related orphan nuclear hormone receptors that play a critical role as xenobiotic sensors in mammals.
Anja Rode, Baes, Bauer, Branko Zevnik, C. Roland Wolf, Dotzlaw, Forrester, Hustert, Jillian Ross, Kocarek, Lowry, Lukas, Meehan, Nico Scheer, Nicole Faust, Poland, Sandra Niehaves, Smith, Wolf, Wrighton   +19 more
core   +4 more sources

A novel dosage form for buccal administration of bupropion

Brazilian Journal of Pharmaceutical Sciences, 2015
Bupropion is an antidepressant used in the treatment of smoking. The purpose of this study was to prepare controlled-release hydrogel films for buccal administration of bupropion and investigate its physicochemical and cytotoxic properties.
Nilsa Maria Galvão Almeida, Renata Lima, Thaís Francine Ribeiro Alves, Márcia de Araújo Rebelo, Patrícia Severino, Marco Vinícius Chaud   +5 more
doaj   +1 more source

Use of Contrave, Naltrexone with Bupropion, Bupropion, or Naltrexone and Major Adverse Cardiovascular Events: A Systematic Literature Review

Diabetes, Metabolic Syndrome and Obesity, 2022
Sarah Dahlberg,1 Ellen T Chang,1 Sheila R Weiss,1 Pamela Dopart,1 Errol Gould,2 Mary E Ritchey3 1Exponent, Inc, Menlo Park, CA, 94025, USA; 2Currax Pharmaceuticals LLC., Brentwood, TN, 37027, USA; 3Med Tech Epi, LLC., Philadelphia, PA, 19147 ...
Dahlberg S, Chang ET, Weiss SR, Dopart P, Gould E, Ritchey ME   +5 more
doaj  

Naltrexone/Bupropion [PDF]

Drugs in R&D, 2010
In March 2010, Orexigen(R) Therapeutics submitted a new drug application (NDA) for approval of naltrexone sustained release (SR)/bupropion SR (Contrave(R)) for the treatment of obesity in the US. The tablet contains naltrexone SR 32 mg and bupropion SR 360 mg.
openaire   +2 more sources